This conference is the industry’s event for antibody and protein therapeutic science and technology in Europe. Nextera is in the forefront of such technology development. Nextera’s CEO, Geir Åge Løset has been invited to present the status of our TCR-like antibody approach. He will show how Nextera’s unique phage display platform NextCore allows for discovery of such hard-to-get antibodies representing a novel class of therapeutic drug candidates for highly specific disease interception.
Link to the conference: https://informaconnect.com/antibody-engineering-europe/.